Gene therapy for HIV infections: Intracellular immunization

Alain Piché MD


Despite significant advances in the treatment of human immunodeficiency virus (HIV) infection in the past 10 years, it remains an incurable disease. The inability of traditional drug-based therapies to inhibit HIV replication effectively for extended periods of time has stimulated intense research to develop novel approaches for this disease. Current understanding of HIV molecular biology and pathogenesis has opened the way for the development of gene therapy strategies for HIV infections. In this context, a number of intracellular immunization-based strategies have been evaluated, and some of them have reached the stage of phase I/II human clinical trials. These strategies include the use of single-chain antibodies, capsid-targeted viral inactivation, transdominant negative mutants, ribozymes, antisense oligonucleotides and RNA decoys. While a number of issues remain to be studied before intracellular immunization can be applied to the treatment of HIV infections, the significant progress already made in this field is likely to lead to clinical applications.

Key Words: Gene therapy; Human immunodeficiency virus (HIV); Intracellular immunization

Thérapie génique pour les infections au VIH : immunisation intracellulaire

RÉSUMÉ : Malgré les grands progrès réalisés dans le traitement de l’infection au virus de l’immunodéficience humaine (VIH) depuis les dix dernières années, cette maladie reste incurable. L’implication de diverses approches thérapeutiques a permis d’obtenir de grands progrès dans le traitement des infections au VIH. Dans ce contexte, un certain nombre de stratégies ont été développées pour la thérapie génique, notamment l’immunisation intracellulaire. Ces stratégies ont atteint le stade des essais cliniques de phase I/II pour l’hépatite B. Les progrès réalisés dans ce domaine risquent de mener à des applications cliniques.

Gene therapy is defined as the genetic modification of somatic cells to correct a disease phenotype or to achieve a therapeutic benefit. Gene therapy is still in its formative stage, being investigated mostly in basic research laboratories. Nevertheless, in the past few years, a number of human clinical trials have been initiated to test important concepts. Preliminary data emerging from these initial trials suggest that gene therapy is a safe approach. Hundreds of patients have been treated in these trials with no reports of major side effects. The rationale for human gene therapy lies in the recent delineation
of the molecular basis of human diseases such as cancer and inherited disorders. In this context, gene therapy offers the unique possibility of correcting diseases at their roots – the abnormal or dysregulated genes.

Despite more than a decade of intense research on human immunodeficiency virus (HIV) pathogenesis aimed at developing effective antiviral drugs and the implementation of highly active antiviral treatments, HIV infection remains an incurable and fatal disease. The mere fact that the HIV genome is integrated into the chromosomal DNA of T lymphocytes renders HIV eradication virtually impossible by conventional antiviral treatments. In addition, high rates of mutation in the viral genome and generation of drug-resistant strains of HIV are major limiting factors that prevent the development of an effective drug-based therapy. Thus, it is clear that alternative approaches to the treatment of HIV infection need to be explored.

The recognition that HIV infection is a true genetic disorder resulting from the acquisition of new genetic material via an infectious process has opened the way for the development of gene therapy strategies for HIV infection. In addition, studies of the underlying mechanisms of the viral infectious cycle and pathogenesis have provided a number of molecular targets that can be exploited in the context of gene therapy. Gene therapy may, therefore, be a novel and potentially effective way to treat HIV infections and prevent AIDS. In theory, this can be achieved in two ways: by preventing de novo infection of susceptible cells by inserting a therapeutic gene before the cell is exposed to the virus and by suppressing ongoing replication in chronically infected cells. In the past few years, a number of phase I/II human clinical protocols have been approved for a variety of diseases. A classification of these protocols is presented in Table 1. Of note, all the protocols approved so far for infectious diseases concern HIV infections.

The term ‘intracellular immunization’ was introduced by David Baltimore in 1988 (1) and refers to any forms of gene-transfer-based cellular resistance to viral infection. In the past few years, a number of intracellular immunization-based strategies have been evaluated for the treatment of HIV infections, some of which are now in human clinical trials. The present paper reviews the different intracellular immunization approaches that have been employed for HIV treatment.

### GENETIC INTERVENTIONS FOR HIV INFECTIONS

The ultimate goal of gene therapy for HIV infection is to inhibit viral replication and prevent the occurrence of AIDS. A variety of strategies have been developed to accomplish gene therapy for HIV infection. These approaches include intracellular immunization, DNA vaccination and immunopotentiation. For each of these strategies, there is a human clinical gene therapy trial directed toward specific HIV targets. Intracellular immunization refers to the efficient and stable transfer of genetic elements that inhibit viral replication. The rationale for immunization with naked DNA plasmid (DNA vaccines) is based on the observation that exogenous DNA is taken up by antigen-presenting cells and elicits an immune response against the protein encoded by the transgene. Immunopotentiation is the modification of a host immune response by altering the specificity or effector function of immune system cells such as T lymphocytes.

#### Intracellular immunization:

Intracellular immunization refers to any forms of gene-transfer-based cellular resistance to viral infection. In contrast with conventional immunization techniques, in which the entire organism is protected against invasion by a pathogen, intracellular immunization consists of the genetic modification of target cells to inhibit or abrogate the replication cycle of a given infectious agent, usually by competing for the binding of proteins that are essential for the replication of this agent. In this strategy, the immunizing moiety is produced inside the cells where it can bind proteins that are usually not accessible by conventional immunization techniques. Thus, the gene encoding the immunizing molecule renders cells resistant to viral gene expression and replication. Intracellular immunization can be accomplished by either protein-based or RNA-based approaches. The therapeutic molecules employed so far, in the context of HIV infection, include transactivation response (TAR) and Rev response element (RRE) decoys, antisense, catalytic RNAs, transdominant negative mutants and single-chain antibodies (sFv). Obviously, the rationale behind the intracellular immunization strategy is to protect uninfected, susceptible cells against HIV infection. Protection of cells may thus persist longer in infected individuals and maintain a therapeutic threshold of immune function. Currents studies focus on gene transfer to mature CD4+ cells, mainly because of the ease of isolation and relative efficacy of transduction, while future studies will introduce antiviral genes into progenitor cells to maintain a renewable source of protected hematopoietic cells.

#### Protein-based approaches – sFvs:

The humoral immune system is extraordinarily diverse and can form literally millions of different kinds of antibodies, each capable of binding just one of the millions of different antigens to which the body may become exposed. Antibodies, displaying high affinity binding properties, have been exploited for identification, purification and manipulation of target molecules.

An important advance in this field was the discovery that monoclonal antibodies could be produced by hybridomas, which were made by fusing a single B lymphocyte with an immortal cell line. Hybridomas can secrete unlimited quantities of a single antibody. Recent progress in antibody engineering
techniques has permitted the isolation of specific antigen-binding sites of immunoglobulins from hybridomas in vitro. Three technical advances in molecular biology have allowed the derivation of the antigen-binding domains of the heavy and light chains to form single-chain fragments. First, it has become possible to express the variable heavy and light chains of antibodies in *Escherichia coli* as single-chain fragments. Second, large repertoires of single-chain fragments can be generated by polymerase chain reaction from mRNA extracted from hybridomas and spleen. Third, efficient techniques are available to select high binding affinity single-chain fragments from repertoires that are specific for a target molecule. These advances have made possible the development of sFVs for therapeutic purposes.

A sFV is the smallest domain region of an antibody that retains the binding specificity of the parental antibody. This single molecule is constructed by linking the heavy and light variable regions using a small flexible linker (Figure 1). In contrast with regular antibodies, sFVs can be expressed intracellularly and directed to different subcellular compartments by the use of appropriate localization signals. Their ability to functionally inactivate virtually any target molecule inside a cell is a clear advantage over regular antibodies. When expressed intracellularly, sFVs bind to their target proteins and sequester the viral proteins in an inappropriate cellular compartment such that the HIV replication cycle is disrupted. Essentially all viral proteins involved in the infectious cycle of HIV have been targeted using this approach. For example, the envelope protein mediates the attachment of the virus to its cellular receptor, and is required both for cell-free and cell-to-cell transmission of the virus. An sFv directed against the conserved epitope of the HIV-1 envelope glycoprotein precursor, gp160, has been shown to inhibit HIV replication and cytopathic syncytium formation by blocking the surface expression of gp120 in a cell culture system (2-4). When targeted to the endoplasmic reticulum (ER) (via appropriate subcellular localization signals), the sFv directed against the HIV-1 envelope protein can bind to this molecule and trap it in the ER, thus preventing maturation of the HIV-1 envelope protein to the surface of the cell. Based on these data, a clinical gene therapy protocol was approved in 1995 by the Recombinant Advisory Committee in the United States.

Other interesting results have been obtained with sFVs targeted to Tat and Rev proteins. Tat acts as a potent transactivator of viral gene expression by activating transcription from the long terminal repeat (LTR). Studies on the effects of anti-Tat sFVs have demonstrated effective sequestration of Tat in the cytoplasm and blockage of its transport to the nucleus (5). Moreover, a marked inhibition of HIV-1 replication was observed in stably transfected cells (6,7). The Rev protein is required for the nuclear export of a subset of HIV-1 mRNAs that encode structural proteins. Cytoplasmic sFVs directed against the C-terminus domain of Rev have demonstrated significant anti-HIV-1 activity. The sFVs abrogated Rev transport to the nucleus, and led to a sustained inhibition of virus replication (8-10). Although potent antiviral activity has been demonstrated with these sFVs, postintegration blockage of HIV-1 replication does not stop the virus from integrating into uninfected cells to maintain a latent infection. A more attractive approach in this context is preintegration blockade of virus replication. Using such an approach, inhibition of HIV-1 replication has been demonstrated with sFVs directed against matrix protein (MA, p17), which is part of the preintegration complex (11), reverse transcriptase (12,13) and integrase (14). However, it should be mentioned that in vivo efficacy remains to be demonstrated.

Intracellular immunization-based strategies are also being considered for AIDS-related malignancies (15). With the improvement of antiviral therapy and prophylaxis against opportunistic infections, HIV patients are now living longer. Hence, there has been a significant increase in AIDS-related malignancies in the past 10 years (16). The different gene therapy strategies for these malignancies were recently reviewed (15). Of note, sFVs have been employed in this context also. An sFv directed against the latent membrane protein 1 (LMP1) of Epstein-Barr virus has been shown to reduce LMP1 protein levels and enhance the sensitivity to chemotherapeutic drugs in Epstein-Barr virus-transformed B lymphocytes (17).

Strategies targeting cellular proteins, such as HIV-1 co-receptors, have also been recently developed. For example, CXCR-4, a transmembrane glycoprotein, is synthesized in the ER and transported to the plasma membrane, where CXCR-4 binds to its ligand (SDF-1) and interacts with the envelope protein of T-tropic HIV-1 virus. In an elegant study by Chen et al (18), T-lymphocytes were genetically modified to stably express the SDF-1 chemokine, the natural ligand of CXCR-4. The SDF-1 molecule was modified and targeted to the ER by the addition of an ER retention signal (SEKDEL). Intracellular ex-
pression of SDF-1 in the ER was able to block the surface expression of newly synthesized CXCR-4. This phenotypic knock-out of CXCR-4 rendered lymphocytes resistant to T-tropic HIV-1 infection. One major limitation of this strategy and the intracellular sFvs approach as a whole is the need to modify genetically a large number of T lymphocytes to achieve significant protection. This seems difficult with the current vectors available for in vitro and in vivo gene transfer.

**Capsid-targeted viral inactivation:** In capsid-targeted viral inactivation, a polypeptide or protein is fused to a virion-associated component to prevent the production of infectious virions and subsequent spread to uninfected cells (19). In this context, a number of HIV-1 accessory proteins, including Vpr, Vif and Nef, are present in infectious virion, in addition to gag, pol and env gene products (20,21). Vpr, together with the matrix protein, facilitates, nuclear transport of the viral preintegration complex in nondividing cells (22). A number of studies have shown that Vpr can be fused to various molecules and still be packaged into HIV particles. The successful incorporation of Vpr into HIV virions when fused to staphylococcal nuclease (23), HIV-1 protease mutant (22,24) and short peptides derived from HIV-1 proteins (25,26) has been demonstrated. Studies on Vpr-fusion constructs have shown an accumulation of Gag/Pol precursors and reduced infectivity of virus progeny in cells transduced with the Vpr-HIV-1 protease mutant plasmids (24), and a delay in HIV-1 replication in cells transduced with Vpr-Vpu polypeptide (22). This is an interesting method that may contribute to the development of an effective antiviral therapy. In addition, Vpr can be fused to a variety of therapeutic molecules, including sFvs and transdominant negative mutants.

**Transdominant negative mutant proteins:** Transdominant negative proteins (TNPs) are mutated versions of HIV-1 proteins that can inhibit HIV-1 replication. TNPs lack wild-type activity and interfere with the normal function of their wild type protein counterpart. TNPs of both regulatory (Tat, Rev) and structural (gag, env) genes have been described (27-30). Perhaps the most investigated TNP is a mutant of Rev protein called RevM10. The RevM10 mutant still binds to the RRE but haps the most investigated TNP is a mutant of Rev protein structural (Tat protein counterpart. TPNs of both regulatory (Tat, Rev) and structural (gag, env) genes have been described (27-30). Perhaps the most investigated TNP is a mutant of Rev protein called RevM10. The RevM10 mutant still binds to the RRE but

**Antisense RNA:** Antisense RNA molecules (ASs) have been widely used for intracellular immunization. They use the specificity of Watson-Crick base pairing to block gene expression in a specific manner. Therapeutic ASs have been used in two forms: short oligonucleotides (15 to 20 acid bases long) and expressed nucleotides (few dozen bases to several thousands). Stable intracellular expression is the most efficient method whereby ASs can be used to inhibit HIV-1 gene expression. In this strategy, the AS molecule is cloned into a retroviral vector and transfected into the target cell. The expressed AS RNA transcripts can then bind to a specific HIV DNA region and inhibit viral transcription. In a recent comparative study, intracellularly expressed AS complementary to various genes of HIV-1 were evaluated (40). The most efficient inhibition of HIV-1 replication was observed with an env AS, leading to 2 to 5 log_{10} reductions in p24 antigen production (a measure of viral activity in the supernatant).

**RNA decoys:** This strategy consists of sequestering nucleic acid-binding viral regulatory proteins by overexpressing short RNA molecules that compete with viral RNAs for binding of
these proteins. The TAR and RRE are examples of such viral regulatory elements. Retroviral-mediated gene transfer of TAR and RRE decoys resulted in marked inhibition of viral replication in vitro (41-43). Although it is clear that TAR and RRE are effective against HIV, they only affect a postintegrative step, and thus this approach would not prevent latent infection.

CONCLUSIONS

A wide variety of gene therapy strategies have been developed that can achieve the significant inhibition of HIV replication in T lymphocytes in vitro, and some of these strategies are now being tested in human clinical trials. It is hoped that these clinical trials will determine whether intracellular immunization or other gene therapy approaches have potential clinical applications in combination with conventional antiviral treatments.

One of the major technical difficulties with the intracellular immunization approach is to transduce stably enough mature T lymphocytes to obtain a clinical benefit. This is true particularly in the context of the rapid turnover of T lymphocytes (half-life of about 6 h) in HIV-infected patients. Moreover, in addition to CD4+ lymphocytes in peripheral blood, a large number of proviral-harbouring cells are located in lymphoid tissue throughout the body (44), cells which may be hard to reach with the approaches discussed above. Because of these limitations, stem cell gene therapy for AIDS is being investigated and offers several potential advantages (45,46). Because HIV primarily infects hematopoietic cells, intracellular immunization of hematopoietic stem cells is particularly attractive. In addition, transduction of even a small fraction of hematopoietic stem cells may lead to the expansion of a significant population of cells resistant to HIV infection.

Gene therapy offers not only the possibility of controlling disease but also eradication of the viral genome in order to cure the infection. More studies are needed to define the therapeutic potential of gene therapy, and there is no doubt that clinicians will hear more about gene therapy for HIV in the next few years.

ACKNOWLEDGEMENTS: I thank Drs Pierre Bourguaux and Raymond Duperval for their helpful comments.


Submit your manuscripts at http://www.hindawi.com